Drug news
Merck Inc. will not submit regulatory applications for anacetrapib its cholesteryl ester transfer protein (CETP) inhibitor.
Merck Inc., has announced that the company will not submit applications for regulatory approval for anacetrapib, its investigational cholesteryl ester transfer protein (CETP) inhibitor. The decision follows a thorough review of the clinical profile of anacetrapib, including discussions with external experts.
Comment: Earlier mixed results with the class of drugs, cholesteryl ester transfer protein (CETP) inhibitors, had posted negative results at Pfizer, Roche and Eli Lilly due to safety issues.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins